Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Objective changes in motor function during placebo treatment in PD.

C G Goetz1, S Leurgans, R Raman

  • 1Department of Neurological Sciences, Rush University, Rush Presbyterian St. Luke's Medical Center, Chicago, IL 60612, USA. mvmtdsrdr@neuro.rush.edu

Neurology
|February 19, 2000
PubMed
Summary

Placebo effects significantly impact objective motor function in Parkinson's disease (PD) during clinical trials. These improvements occur across all motor domains and throughout a 6-month study period.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same author

Revue neurologique·2017
Same author

Charcot, hysteria, and simulated disorders.

Handbook of clinical neurology·2016
Same author

Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.

European journal of neurology·2014
Same author

Continuous in-home monitoring of essential tremor.

Parkinsonism & related disorders·2013
Same author

Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale.

European journal of neurology·2013

Area of Science:

  • Neurology
  • Clinical Trials
  • Parkinson's Disease Research

Background:

  • Placebo effects are recognized in neurological disorders.
  • The temporal dynamics and specific motor impairments influenced by placebo in Parkinson's disease (PD) remain underexplored.

Purpose of the Study:

  • To quantify the frequency, timing, and consistency of motor improvements during placebo treatment in PD patients.
  • To identify which clinical domains and patient demographics are most affected by placebo responses.

Main Methods:

  • Analysis of the placebo arm from a randomized, multicenter trial involving 105 PD patients without motor fluctuations.
  • Assessment of placebo effects on the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS) over 6 months (baseline, 4, 12, 24 weeks).

Related Experiment Videos

  • Utilized a strict definition for placebo-associated improvement (≥50% UPDRS motor score improvement or ≥2 points on ≥2 items).

    • Main Results:

    • 16% of participants showed improvement during placebo treatment over 6 months.
    • Placebo response prevalence remained consistent (8-9%) at each visit, without an early effect predominance.
    • Improvements were observed across all motor domains (tremor, bradykinesia, rigidity, gait/balance), with a trend towards greater response in bradykinesia and rigidity.

    Conclusions:

    • Rigorous analysis reveals significant placebo-associated improvements in objective PD motor measures within clinical trials.
    • Placebo effects manifest throughout a 6-month trial, necessitating studies of this duration to fully capture these responses.
    • Placebo-controlled studies in Parkinson's disease should be at least 6 months long to account for both early and late placebo effects.